Ocular Stem Cell Research from Basic Science to Clinical Application: A Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium.
Ocular Stem Cell Research from Basic Science to Clinical Application: A Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium.
复制标题
DOI：
10.3390/ijms17030415
复制
发表时间：
2016-03-22
影响因子：
5.6
通讯作者：
Zack DJ
中科院分区：
文献类型：
--
作者：
Ouyang H;Goldberg JL;Chen S;Li W;Xu GT;Li W;Zhang K;Nussenblatt RB;Liu Y;Xie T;Chan CC;Zack DJ
干细胞有望治疗多种疾病，包括眼睛退行性疾病。眼睛是干细胞治疗的理想器官，因为它具有相对的免疫学特权、手术可及性以及它是一个独立的系统。眼睛还有许多适合干细胞治疗的潜在目标疾病，例如角膜缘干细胞缺乏、青光眼、年龄相关性黄斑变性（AMD）和色素性视网膜炎（RP）。其中，AMD和青光眼是两种最常见的疾病，影响全球超过2亿人。最近在美国、日本、英国和中国进行的来自人类胚胎干细胞 (hESC) 和诱导多能干细胞 (iPSC) 的视网膜色素上皮 (RPE) 细胞治疗干性 AMD 和 Stargardt 病的临床试验结果引起了极大的兴奋和希望。这标志着眼部干细胞治疗时代的开始。最近举行的中山眼科中心眼干细胞研讨会讨论了各种干细胞类型在干细胞疗法、药物发现和组织工程治疗眼部疾病方面的潜在应用。
Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt’s disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.